Endometriosis drives costly care long before diagnosis arrives
Endometriosis is often framed as a gynecologic diagnosis, but the economic burden begins much earlier, when symptoms scatter across specialties and the condition remains unrecognized. Nomi Health’s analysis looked at the year before first observed diagnosis and found a pattern of repeated care, diagnostic detours, and rising costs that preceded confirmation of the disease. The numbers point to a familiar clinical problem: when pelvic pain, heavy bleeding, anemia, back pain, sciatica, migraine, or gastrointestinal complaints are treated in isolation, the underlying disorder can remain hidden for years.
The condition itself is common enough to matter at population scale and disruptive enough to alter work, family life, and fertility planning. Endometriosis is caused by tissue similar to the uterine lining growing outside the uterus, including on the ovaries, fallopian tubes, cervix, bladder, or rectum. Even though it is not typically life-threatening, it can be profoundly disabling. Severe pelvic pain, abdominal pain, heavy menses, breakthrough bleeding, painful intercourse, and infertility all create clinical and social consequences that extend well beyond a single office visit.
One sentence captures the central failure of the current pathway: women can spend years seeking an explanation for pain that is dismissed as routine.
A one-year claims window exposed repeated detours
The analysis used a large employer and health plan data set and focused on women with at least 24 months of enrollment who later received a first observed diagnosis of endometriosis. Investigators then looked back 12 months from diagnosis and examined medical and pharmacy claims tied to the conditions most often seen before the disease is finally recognized. To keep the work grounded in real-world utilization, the review centered on the 15 to 20 most common overlapping diagnoses, including pelvic pain, pelvic inflammatory disease, sciatica, chronic back pain, chronic fatigue, iron deficiency anemia, very heavy bleeding, migraines, and other related complaints.
This design matters because endometriosis rarely announces itself in a straight line. A patient may present first to primary care with back pain, then to gastroenterology for abdominal complaints, then to orthopedics for sciatica, and later to gynecology after symptoms continue or infertility becomes part of the story. Each encounter may be clinically reasonable on its own. The problem is cumulative. Diagnostic fragmentation drives repeated testing, repeated visits, and repeated spending before anyone connects the pattern to a pelvic disease process that often requires laparoscopic surgery and biopsy for definitive confirmation.
Prediagnosis spending reached nearly $37 million a year
Across the women identified in the data set, the number of first diagnoses each year was fairly stable, landing at roughly 21,000 to 23,000 cases annually. When investigators summed the costs tied to those overlapping conditions in the 12 months before diagnosis, the total came to almost $37 million a year. On a per-person basis, the average spend was about $1,800 annually for care during that prediagnosis period.
The figure is not a full accounting of endometriosis costs, and it does not capture the burden after diagnosis or the broader losses tied to missed work, reduced productivity, or personal disruption. It does, however, show how expensive uncertainty can become. In an employer-sponsored or health plan environment, repeated specialty visits and symptom-based treatment can accumulate quietly until the bill becomes visible only in hindsight. For a condition with a diagnostic delay that can stretch from four to 11 years, even one year of prediagnosis claims is enough to suggest substantial waste and avoidable strain.
Specialty hopping reflects the biology of a disease that mimics many others
Endometriosis is difficult to diagnose because its symptom profile overlaps with several common disorders. Pelvic pain may be mistaken for gynecologic cramping, urinary symptoms can resemble bladder disease, bowel complaints can look like inflammatory bowel disease, and chronic pain syndromes may pull patients toward rheumatology or orthopedics. The biology explains the confusion. Ectopic endometrial-like tissue can provoke inflammation, scarring, and pain across multiple anatomic sites, which means the presentation often depends on where the lesions sit and how they irritate surrounding tissue.
At the bedside, that means a patient may receive useful but incomplete care for years. Analgesics, hormonal treatments, iron replacement, imaging, and referrals may each address one piece of the picture without solving the underlying disorder. When infertility becomes the reason for further evaluation, the diagnosis may finally emerge during laparoscopic exploration. For some women, the disease is obvious because of pain and bleeding. For others, it stays hidden until conception does not happen as expected.
The real clinical consequence is not just delay. It is misdirection.
Diagnostic delay remains the most expensive part of the disease pathway
The analysis reinforces a simple point with broad implications for employers, payers, and clinicians: the greatest cost may come before the diagnosis is even named. When a condition is under-recognized, the health system spends time and money on repeated workups rather than targeted treatment. That delay is especially consequential in endometriosis because the disease affects reproductive-age women, can impair fertility, and often requires surgical confirmation. The longer the delay, the longer symptoms can erode functioning, relationships, and the ability to sustain work without interruption.
For employers, the burden is likely to show up as absenteeism, presenteeism, and recurring claims across unrelated service lines. For health plans, the signal is scattered utilization rather than a single high-cost event. For clinicians, the lesson is to treat recurring pelvic pain, severe bleeding, anemia, and unexplained multisystem symptoms as potential clues rather than isolated complaints. The data make clear that earlier recognition could reduce some of the downstream spending now absorbed by repeated diagnostic searches.
The analysis also aligns with a larger push from major professional organizations to shorten the time to diagnosis. That effort is clinically important because endometriosis is common, under-recognized, and frequently missed precisely where care is supposed to be most coordinated. The remaining question is not whether the disease creates cost; it already does. The harder problem is how to shorten the path from first symptom to definitive evaluation before another cycle of fragmented care begins.